CDY1 and Miyoshi myopathy: Using the CDy1 efflux assay, it has been reported that a subpopulation of MM cells overexpressing membrane P-gp and mRNA showed resistance to carfilzomib, a second-generation proteasome inhibitor approved for therapy-refractory MM.